Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis: pooled interim results for up to 3 years from the ASSURE study

E J Lawitz, P J Trivedi, K V Kowdley, S C Gordon, C L Bowlus, M C Londoño Hurtado, G M Hirschfield, A Gulamhusein, M Demir, D B Crittenden, S Zhuo, C Heusner, C Levy · Zeitschrift für Gastroenterologie · 2025 · Heft 08 · S. e375-e376